ArticleIndian journal of orthopaedics2025
Multifocal Spinal Intradural Myxopapillary Ependymoma.
Article in Indian journal of orthopaedics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ependymal tumors constitute approximately 1.8% of all primary central nervous system (CNS) tumors. Myxopapillary ependymomas (MPEs), a subtype of ependymoma, account for nearly 15% of spinal ependymoma cases. Multifocal presentation of MPEs at the initial diagnosis in adults is exceedingly rare, with only 12 such cases reported in the literature between 2011 and 2024. Despite generally favorable prognoses, MPEs are associated with a high risk of recurrence, emphasizing the need for long-term surveillance. Case Presentation: We report a case of a 21-year-old male presenting with lower back pain and right-sided foot drop. MRI revealed multiple intradural extramedullary lesions at D12-L3, L4-L5, and S1-S2 levels. Gross total resection (GTR) was performed, and histopathology confirmed the diagnosis of myxopapillary ependymoma. Postoperative recovery included significant neurological improvement. However, 6 months post-surgery, the patient developed a new lesion at the D3 level along with metastases at D12 and S2, prompting the initiation of whole-spine irradiation. Conclusion: Myxopapillary ependymomas are rare WHO grade II spinal tumors with a tendency for multifocality and recurrence. GTR remains the cornerstone of treatment for optimal outcomes. In cases where GTR is not feasible, adjuvant radiotherapy is recommended. Ongoing studies are warranted to better determine the indications for craniospinal irradiation versus localized radiotherapy in such cases. Supplementary Information: The online version contains supplementary material available at 10.1007/s43465-025-01467-6.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.